As Sun Sets On Copaxone, Teva Looks To New BD Horizons
This article was originally published in The Pink Sheet Daily
Executive Summary
Acting CEO Eyal Desheh said the company will be more open-minded about business development during the company’s fourth quarter financial call Feb. 6. Investors will have to wait to hear from incoming CEO Erez Vigodman for any new strategy to be articulated, however.
You may also be interested in...
Emerging Markets Earnings Roundup: Sanofi, Teva (Part 7)
Sanofi shows solid growth in emerging markets in the fourth quarter, including an impressive 35.1% gain in China. Teva in transition offers scant detail on emerging markets, but hints larger deals possible in 2014.
Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?
Wall Street is mixed on whether Teva’s newly approved three-times-weekly formulation will protect its MS blockbuster franchise.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.